MAP3K12

Across TCGA pan-cancer cohorts, MAP3K12 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MAP3K12 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher MAP3K12 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAP3K12 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM are the cancer types where MAP3K12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.838	0.632	.018	9	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

MAP3K12–GBM (DFS)

Open the GBM breakdown →